ES 013
Alternative Names: ES-013Latest Information Update: 28 Sep 2020
At a glance
- Originator Elpiscience Biopharmaceuticals
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 28 Sep 2020 ES 013 is available for licensing as of 28 Sep 2020. http://www.elpiscience.com/
- 28 Sep 2020 Early research in Cancer in China (Parenteral) (Elpiscience Biopharmaceuticals pipeline, September 2020)
- 28 Sep 2020 Elpiscience Biopharmaceuticals plans CMC evaluations in Cancer, between 2021 and 2023 (Elpiscience Biopharmaceuticals pipeline, September 2020)